To date, EpCAM overexpression has been indicated to be able to predict poor prognosis of the patients with renal cancer [19], breast cancer [8], prostate cancer [20], ovarian cancer [21] and hypopharyngeal cancer [22], while its prognostic value was controversial in lung cancer. Here, EPCAM is linked to renal carcinoma.